Illumina, Inc. (ILMN) Earnings Call Transcript & Summary
February 7, 2023
Earnings Call Speaker Segments
Sallilyn Schwartz
executiveGood day, everyone, and thank you for joining us for the earnings call covering the fourth quarter and full year 2022. On today's call, we'll go through the financial results that were issued after the market closed and share some commentary on our commercial activity, and following that, we'll open things up for a question-and-answer session. If you haven't yet had the opportunity to look at the earnings release, you can find it in the Investor Relations section of our website at illumina.com. Joining us from Illumina today are Francis deSouza, President and Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer. Francis will give an update on how Illumina's business is performing, and Joydeep will walk through our financial results, which include GRAIL. As a reminder, under the interim measures ordered by the European Commission, which blocked our acquisition of GRAIL under the EU merger regulation, GRAIL has to be held and operated separately and independently from Illumina. This call is being recorded, and the audio portion will be archived in the Investors section of our website. It is our intent that all forward-looking statements about our financial results and commercial activity made on today's call will be protected under the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainties. Actual events or results could differ materially from those projected or discussed. All forward-looking statements are based on information currently available, and Illumina assumes no obligation to update those statements. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents Illumina files with the Securities and Exchange Commission, including Illumina's most recent Forms 10-Q and 10-K. With that, I'll now hand the call over to Francis.
Francis deSouza
executiveThanks, Salli, and good afternoon, everyone. For Illumina and for genomics, 2023 has gotten off to an exciting start, and I'm pleased to share that the first NovaSeq X Plus systems are now headed to customers. In a bit, I'll walk through how we are adding manufacturing and distribution capacity so we can ship 40 to 50 units in Q1 and more than 300 units over the course of the year. First, though, I'll go over the financial results for the fourth quarter and for all of 2022. Illumina's fourth quarter revenue came in at roughly $1.1 billion, and revenue for the full year 2022 was roughly $4.6 billion, which puts us at the upper end of the revised guidance range we gave. During 2022 we placed over 3,200 instruments, which lifted our installed base worldwide to roughly 23,000 instruments. Let me now go through each of our platforms, beginning with high-throughput. Customer response to the NovaSeq X series launch has been fantastic. Orders keep growing, and so does the advanced pipeline. Global interest is strong, with orders coming from more than 25 countries — 4x the number seen in the first quarter of the NovaSeq 6000 launch. Clinical adoption is also exceeding expectations, and we're seeing orders from new to high-throughput customers who are moving sequencing in-house, drawn by NovaSeq X's ease of use and cost benefits. When you look at every instrument launch Illumina has done, the NovaSeq X has the strongest pre-order book of them all, and that level of demand is going to fuel an upgrade cycle lasting multiple years. We shipped more than 340 NovaSeq 6000 units in 2022 as well, and over a third of those systems were used for oncology testing, while close to half were placed with customers who were new to high-throughput or new to Illumina. Placements remained solid through the first half of 2022, even after a record-setting 2021. During the second half, placements slowed as customer excitement about the NovaSeq X series grew. Across the full year 2022, average consumable pull-through for the NovaSeq 6000 was roughly $1 million per instrument. Now moving to mid-throughput. During 2022, we delivered 1,215 instruments — a record — and that made it the fourth year in a row of record NextSeq shipments. Q4 2022 also stood as the strongest quarter ever for NextSeq 1000/2000 shipments. What customers appreciate about NextSeq 1000/2000 is its distinctive set of capabilities: no other mid-throughput sequencer has integrated analysis built in, and it was the first mid-throughput instrument to offer the 2x300 kits. Of the NextSeq 1000/2000 units sold in 2022, close to 25% were purchased by customers who were new to Illumina. Turning to low-throughput, roughly 1,670 instruments went out in 2022, which added almost 700 first-time Illumina customers. Our low-throughput instruments keep opening up new geographies and applications, and they serve as an effective gateway into sequencing. Let me now move on to our markets. Our clinical markets at present cover oncology testing, reproductive health, and genetic disease. Clinical customer shipments accounted for 45% of core Illumina consumables during 2022. Oncology testing consumables climbed 7% year over year in 2022, fueled by MGS-based molecular profiling use in early detection, therapy selection, and minimal residual disease. Worldwide, we foresee expanding opportunities for our oncology offerings; sample volume for our TruSight Oncology 500 distributed therapy selection assay rose roughly 60% year over year across over 500 accounts. Looking toward 2023, we expect TSO 500 revenue to exceed $100 million. Also in oncology, GRAIL continues to experience strong demand from consumers, physicians, health systems, and payers. Galleri stands as the sole multi-cancer early detection test within a market worth $40-plus billion, and it delivered the quickest first-year revenue ramp ever seen in cancer screening testing. GRAIL has built more than 60 partnerships with leading health systems, self-insured employers and other health care stakeholders; during 2022 by itself, over 4,500 providers placed orders for the test, which contributed to the more than 60,000 Galleri test orders received so far. The Galleri test has been granted FDA Breakthrough Designation and was highlighted by Time as one of the best inventions of 2022, by The Atlantic as one of the Breakthroughs of the Year and by Fast Company as one of the world-changing ideas of 2022. Galleri additionally appeared in an AARP health story covering game-changing medical breakthroughs that are improving lives today. GRAIL anticipates that this exciting momentum will persist and convert into an expected revenue CAGR of 60% to 90% across the next 5 years. Outside oncology, genetic disease testing delivered a record quarter in Q4 along with another strong year in 2022. During 2022, GDT consumable shipments rose 11% year-over-year, fueled by wider adoption of whole genome sequencing around the world and greater demand for rare disease treatment. We saw additional evidence being generated. The European Society of Human Genetics revised its guidelines, recommending wider use of whole genome sequencing in diagnostics and expanded coverage for rare and undiagnosed genetic diseases. Recently, the two largest U.S. health insurance companies by patient count announced that whole genome sequencing would be covered for patients with rare and undiagnosed genetic diseases starting this quarter. Additionally, AIM Specialty Health, which provides lab benefits management services to more than a dozen regional health plans across the U.S., now considers comprehensive genomic profiling medically necessary for appropriate patients with advanced cancers. Dozens of millions of additional Americans are going to obtain coverage — an enormous victory for patients, for our customers, and for Illumina. Moving on to the research and applied segments of our business. In 2022, consumable shipments made up 55% of core Illumina consumables. For our customers, increasing diversity within genetic databases is a major priority as they seek to grasp what lies beneath disease. When genomics is paired with clinical information, it can improve the odds of success in drug discovery by as much as 150% while reducing costs by as much as 50%. Reaching that goal requires more samples gathered over time and drawn from a wider range of populations; we recently disclosed an agreement with Amgen and its subsidiary, deCODE Genetics, to sequence the initial 35,000 genomes within our collaboration with Nashville Biosciences. This sample group will constitute the biggest collection of African-American data so far, since our goal is to speed up fair access to precision health treatments, and sequencing of the initial samples is already underway. Turning to 2023 now. We're very excited about this launch year, and we've started sending NovaSeq X Plus systems to our first customers; we're still on track to ship 40 to 50 NovaSeq X instruments in Q1 and more than 300 instruments over the course of 2023. To achieve that, we broadened our operational capacity. We've built state-of-the-art consumable manufacturing facilities in the U.K., Singapore and San Diego, which brought 9 new production lines. When we launched, we already had two to three months of inventory on hand for all six of the core consumable SKUs. Down at our instrument plant in Hayward, we've finished hiring, and production and capacity are now being scaled up. Right now, more than 60 NovaSeq X instruments are at different points along the manufacturing line. All of the primary and secondary sequencing metrics are at or above spec. On top of that, we've done things to keep the supply chain solid. We began bringing on and qualifying additional suppliers two years back so we'd have the materials and components needed for NovaSeq X output secured. We're getting our worldwide sales force ready to assist customers when the initial NovaSeq X units ship; back in January, we brought together over 800 members of our sales team for a training session lasting 3 days, giving them fresh tools and insights so they can help customers speed up genomics across the globe using this powerful new instrument. The team is energized about taking these new capabilities to market and eager to see what years of preparation will produce; we're confident that our organization's scale, reach and experience will enable our customers to sequence more samples, run more analyses and obtain more data than ever before; and NovaSeq X unlocks greater elasticity, so we expect average pull-through for the X to comfortably surpass NovaSeq 6000 over time. Illumina is going to keep its attention on backing our valued customers through transformative innovations, and we will continue moving our road map forward to speed up the genome era. Interest from customers globally is still very strong, and they are keen to take advantage of what the X can do — the most powerful, most sustainable, and most cost-effective sequencer we have ever developed — so they can further unlock the power of the genome. At AGBT this week, you will hear more about the customer experience and the data. Now, before I pass the call to Joydeep, I want to thank him and welcome him into his new position as Illumina's Chief Financial Officer. Joydeep joins us having spent over 20 years in this sector, and he contributes strategic acumen, thorough familiarity with the industry, and wide-ranging international business experience. A disciplined and battle-tested leader, he has demonstrated a solid history of generating value, making him the right collaborator to help steer Illumina's coming stage of expansion. At this point I'll hand things over to Joydeep, who will walk you through the quarter's details and what we expect for the entire year.
Joydeep Goswami
executiveThanks, Francis, and I appreciate the warm welcome. It's great to be taking on this role permanently and to keep collaborating with everyone here. First, I'll walk through the consolidated financial results, then cover segment results for core Illumina and GRAIL, and finish with some additional comments about how we see 2023 shaping up. My remarks will focus on non-GAAP results, which include stock-based compensation. Please take a look at the GAAP reconciliation of those non-GAAP measures, available in today's release and in supplementary data posted on our website. Consolidated revenue for the fourth quarter came in at $1.8 billion, a decline of 10% versus the prior year, or 7% lower in constant currency, net of hedging effects. Non-GAAP earnings were $22 million, or $0.14 per diluted share, and that includes dilution from GRAIL's non-GAAP operating loss of $159 million in the quarter. Non-GAAP EPS fell short of expectations, largely because of roughly $87 million in incremental tax expense tied to the R&D capitalization requirements that were not repealed in Q4 2022 despite broad bipartisan support. That incremental tax expense includes about $80 million recorded in Q1 through Q3 that ultimately was not reversed in Q4. Our non-GAAP tax rate came to 29.3% for the quarter and 26% for full year 2022, up from 15.6% in Q4 2021 and 17.3% in fiscal year 2021, mainly reflecting the impact of R&D capitalization requirements. Non-GAAP weighted average diluted shares for the quarter totaled approximately 158 million. Now on to segment results. I'll begin with core Illumina's financial performance. Core Illumina revenue was $1.07 billion, down 11% from a year earlier, or down 8% in constant currency, net of hedging effects. Core Illumina sequencing consumables revenue of $687 million declined 13% year-over-year. As anticipated, growth from pull-through on the larger installed base was offset by delayed recruitment on certain large research projects in the Americas and Europe, continued COVID disruptions in China, the year-over-year effect of customer inventory management, the expected drop in COVID surveillance revenue, and foreign exchange headwinds. Sequencing instruments revenue at core Illumina dropped 24% year-over-year to $146 million, primarily because of fewer NovaSeq 6000 shipments ahead of NovaSeq X availability. That decline was partly offset by another quarter of record NextSeq 1000/2000 shipments, which rose 31% year-over-year as we continue to see strong adoption among customers new to Illumina and demand for our new 2x300 kits that bring longer lead capabilities to our mid-throughput platform for the first time. In the fourth quarter, COVID surveillance contributed about $20 million in total revenue, made up of $19 million in sequencing consumables and $1 million in sequencing instruments. That matched our expectations and was down $30 million year-over-year, mainly on lower sample volumes. Core Illumina sequencing service and other revenue came in at $131 million, a 24% increase year-over-year. The main drivers were higher instrument service contract revenue on a growing installed base, along with growth in oncology and IBD partnership revenue. Now turning to regional results for core Illumina. Americas revenue was $577 million, a 7% decline year-over-year, while EMEA revenue of $301 million fell 14% year-over-year, or 10% on a constant currency basis. As we expected, the base business in both regions felt the impact of customers holding off ahead of NovaSeq X and the slowdown in COVID surveillance and research that I mentioned earlier. Demand for NextSeq 1000/2000 remains strong, with record shipments in the Americas, up nearly 50% year-over-year, powered by strength in both research and clinical. On top of that, NovaSeq Dx shipments beat expectations in the first quarter of launch, with strong early demand from clinical customers in Europe. Greater China revenue of $94 million was down 22% year-over-year, or 14% on a constant currency basis. The region kept feeling the effects of COVID lockdowns, which led to lower sample volumes year-over-year. We still expect our China business to face headwinds from COVID-related disruptions, exchange rates and slowing GDP growth in the region, at least through the first half of 2023. Lastly, APJ revenue of $93 million declined 10% year-over-year, or 4% on a constant currency basis, net of hedge effects. Strong growth across clinical markets was more than offset by the completion of a large research project in Japan and delayed high-throughput instrument purchases tied to the introduction of NovaSeq X. Shifting to the rest of the core Illumina P&L. Core Illumina non-GAAP gross margin was 67.3%, down 430 basis points year-over-year, mainly because of less fixed cost leverage on lower manufacturing volumes. Core Illumina non-GAAP operating expenses were $528 million, down $52 million year-over-year, primarily from cost containment initiatives, lower performance-based compensation expense and a onetime partnership-related expense in Q4 2021. Now moving to GRAIL's financial results. GRAIL revenue for the quarter was $23 million, up 130% year-over-year, driven mainly by accelerating adoption of Galleri and higher contributions from MRD pharma partnerships thanks to a milestone payment in Q4 '22 that GRAIL does not expect to repeat in Q1 2023. GRAIL non-GAAP operating expenses totaled $166 million, an increase of $35 million year-over-year, driven primarily by continued investments in clinical trials and scaling GRAIL's commercial organization. Turning to consolidated cash flow and balance sheet items. Cash flow provided by operations was $147 million. Fourth quarter 2022 capital expenditures were $88 million, and free cash flow was $59 million. We did not repurchase any common stock in the quarter. We closed the quarter with approximately $2 billion in cash, cash equivalents and short-term investments. At quarter end, cash included $991 million in net proceeds from term notes issued on December 13, 2022, and those funds are going to be used to repay debt maturities coming up in 2023. Now turning to guidance for 2023. For the full year, we expect consolidated revenue growth of 7% to 10%, reaching roughly $4.9 billion to $5.03 billion. For full year 2023, core Illumina revenue is expected to grow 6% to 9%, to approximately $4.83 billion to $4.96 billion. Those ranges factor in an anticipated headwind of roughly 200 basis points from COVID surveillance, plus a year-over-year headwind from foreign exchange rates. Quarterly revenue should ramp sequentially through 2023, with linearity trends comparable to 2017, when we launched the NovaSeq 6000. GRAIL is expected to deliver revenue between $90 million and $110 million for 2023, which reflects year-over-year growth of 82% at the midpoint, driven by accelerating adoption of the Galleri test. For fiscal 2023, at the midpoint of our revenue guidance range, we expect core Illumina sequencing revenue to grow approximately 8% year-over-year. That figure includes intercompany sales to GRAIL of approximately $35 million, which get eliminated in consolidation. We expect core Illumina sequencing instrument growth of approximately 9% year-over-year, driven by the NovaSeq X upgrade cycle and continued momentum in mid-throughput; for core Illumina sequencing consumables, we expect growth of approximately 8% year-over-year, primarily driven by the NovaSeq X launch as customers build consumables inventory and ramp utilization, as well as continued growth in our mid-throughput consumables due to the growing installed base.
Joydeep Goswami
executiveThat increase is going to be partly offset by additional declines in COVID surveillance revenue. For the NovaSeq 6000, we anticipate annual pull-through of roughly $900,000 to $1 million per system in 2023, as customers make the move to NovaSeq X. For NextSeq 1000/2000, we anticipate pull-through between $120,000 and $170,000 per system in 2023, as the record instrument placements from '22 and continued strong placements in 2023 come fully online. For the rest of our pull-through ranges, we anticipate they will be consistent with historical guidance. In addition, we anticipate roughly $30 million of revenue from COVID surveillance in 2023, representing a year-over-year headwind of $105 million, or about 2 percentage points. We anticipate a consolidated non-GAAP operating margin of roughly 8% and a core Illumina non-GAAP operating margin of roughly 22% for 2023. Those margins reflect: one, higher core Illumina operating expenses versus 2022, mainly from normalization of our performance-based compensation; two, a temporary decline in gross margins as we launch NovaSeq X, in line with what we saw in 2017 at the launch of NovaSeq 6000; and three, higher GRAIL operating expenses from ongoing investments to support the FDA application, the NHS trial, and continued scaling of GRAIL's commercial organization; we also anticipate a consolidated non-GAAP tax rate of roughly 36%, which includes an impact of roughly $75 million from the R&D capitalization requirements. Should those requirements be repealed in 2023, we anticipate our 2023 non-GAAP tax rate to be roughly 15%; we anticipate consolidated non-GAAP earnings per diluted share between $1.25 and $1.50, which includes dilution from GRAIL's non-GAAP operating loss of roughly $670 million; and lastly, we anticipate non-GAAP diluted shares outstanding for fiscal 2023 of roughly 160 million shares; for the first quarter of 2023, we anticipate consolidated revenue between $1.05 billion and $1.07 billion for Q1 2023, reflecting a sequential decline of 212 basis points from Q4 2022 at the midpoint, mainly driven by: historical seasonality of our core business because year-end budget flushes will not repeat in the first quarter; partly offset by higher high-throughput instrument shipments from the Q1 launch of NovaSeq X; and a decline in GRAIL revenue of roughly $5 million due to a milestone payment in Q4 2022; we anticipate quarterly revenue to grow sequentially through 2023, driven by a ramp in NovaSeq X shipments and utilization, recovery from COVID disruptions in China, accelerating adoption of Galleri, and an expected mitigation of macroeconomic headwinds in the second half of 2023; for the first quarter, we anticipate a consolidated non-GAAP operating margin of roughly 1% and a core Illumina non-GAAP operating margin of roughly 17%; we anticipate operating margins to improve throughout 2023 as revenue ramps and we scale our production of NovaSeq X and leverage the fixed cost of the manufacturing base. We anticipate net other expense of roughly $9 million, mainly due to interest expense on our new bond issuances. And finally, for non-GAAP diluted shares outstanding, we're expecting roughly 160 million shares, which is consistent with fiscal 2023. At this point I'll turn things back to Francis so he can offer his closing comments.
Francis deSouza
executiveThanks, Joydeep. Innovation stays a top priority for Illumina; we recognize that what our customers are really investing in is our road map, and not simply our instruments. I discussed the NovaSeq X series a bit earlier. The X serves as a strong catalyst for 2023 and past that. Sustainability was another priority for us. Compared with the NovaSeq 6000, NovaSeq X delivers a 90% cut in packaging waste and weight, along with a 50% cut in plastic usage. Shipping reagents at ambient temperature, once enabled, will save close to 500 tons of dry ice annually while substantially lowering waste streams for our customers; these gains are true game changers for our industry. We're also eager to launch long-read capabilities through 2 forthcoming products within our Illumina Complete Long-Reads offering. The long-read human whole genome assay comes to market in the first half of this year, and the enrichment panel arrives in the second half of this year. We announced recently that our enrichment panel will deliver a comprehensive, high-accuracy, long-read view for as little as $600 per genome. Over a dozen customers have assessed data from their own samples with Illumina Complete Long-Reads, and their responses have been extremely favorable. They consider Illumina Complete Long-Reads handier than competing long-read technologies and simpler given the flexible input requirements; the data accuracy impresses them, as do the read lengths and phase blocks that Illumina sequencers can produce. Illumina Complete Long-Reads and NovaSeq X will keep advancing the genomics field; this year marks Illumina's 25th anniversary, which we will celebrate. Across this quarter century, Illumina has stayed at the leading edge of a worldwide genomics movement, and our optimism about what lies ahead is even greater; we're honored to drive a global health transformation alongside our customers. And together, we will capture the potential of the genome era. I'll now ask the operator to open the line for Q&A. Thank you.
Puneet Souda
analystCongratulations on the permanent position, Joydeep. My first question: at AGBT we saw you had 150 orders as of this morning, which is 10 more than at the beginning of this year. I just wanted to clarify that the increase was only 10 relative to the advanced pipeline prospects. Maybe you can give us that figure. I appreciate that you're giving the full-year 300-plus number, but previously, if I recall, advanced pipeline prospects were 200-plus, so could you clarify how much that grew, since the increase here within a month was somewhat lower than we had anticipated. And then I wanted to clarify with you, Francis, what are you hearing from customers among those advanced pipeline prospects? What exactly are they after right now? What needs to happen before their interest converts into orders? Do they need customer validation, data, or something else? That would really help.
Francis deSouza
executiveAbsolutely. Thanks, Puneet; I'll start with the numbers, since you asked for them. Customer demand for the X series, as we've said, has been very strong and has come in above what we expected. And as you mentioned, we recently reported that 340 instruments were spoken for, with 140 of those in preorders and 200 in advanced pipeline. That momentum continued over the past few weeks in January, and now we have over 155 instruments in preorders and over 250 in advanced pipeline. You've watched how things developed through January. Going forward, our plan is to keep you posted each quarter—same as always—on order performance, and since we've now started shipping, we'll naturally include shipment updates as well. From customers moving through the pipeline, the feedback is that they're genuinely enthusiastic about several items we anticipated they'd respond to; they love what the X series can do in terms of handling far more samples at once than was previously possible, and the economics of operating the X have them very excited. They are just as enthusiastic about the sustainability elements we designed into the X — the cut in plastic and waste, along with removing the requirement for dry ice during shipping. All of that, taken together with the simplicity of operation they're noticing — when we walked them through the specifications at IGF, they grasped the power, the performance, and the quicker turnaround. Yet one aspect that has, I believe, happily caught people off guard once they actually engage with the X is how much we've put into making the workflow easy to use. This represents an even bigger advance beyond the prior state-of-the-art with the 6000, and what it enables is for sequencers to be operated by a technical team that isn't as — you don't necessarily need a genomics degree, for instance; so that expands workforce capabilities for them. Now, what research customers tell us is that, more and more, they're beginning to view the X as essential when it comes to staying competitive for grants and grant dollars. So we're starting to see people incorporate that into their planning around grant applications; on the clinical front, what we're told is that because of the better workflow performance and cost associated with the X, clinical customers are building their new assays and tests on the X, expecting that's how they'll launch new testing. Meanwhile, they're starting to want to get acquainted with the workflow so they can plan a move of their existing tests over to it. That will take more time; so the initial demand from clinical customers relates to new testing they wish to perform on the X. That represents a portion of what we're hearing back from clients.
Joydeep Goswami
executiveYes, and Puneet, thanks so much first of all for those nice remarks. I think the other thing you were asking about is what exactly customers are waiting on to move from the funnel into orders, correct? And remember, this is the late-stage funnel, so interest has already been confirmed. They like what they're seeing, as Francis said, and they can see where the budget will come from, right? So typically it comes down to the timing of when that budget arrives — perhaps they're wrapping up or finalizing some of the grants, which is what pushes them into placing orders; and we absolutely expect that to play out over the course of the year, just as we've observed in prior years.
Dan Brennan
analystJoydeep, well done. Maybe I'll begin with the guidance. From what I remember at JPMorgan, you folks described the '23 guide as having been built on a conservative approach. I'm just wondering, after what unfolded in the back half of '22, whether anything has been learned? Has the way you guide changed in any respect? Could you take us through a bit regarding that conservatism, or whatever way you'd prefer to quantify it, that's embedded in the '23 guide? I know, Francis, you folks put numbers on a fair amount of the headwinds, kind of. I'm just curious how much perhaps you've factored in in total for those headwinds, or however you'd prefer to talk about the process and the conservatism. And then just, second, just on GRAIL.
Joydeep Goswami
executiveSure, Dan. Thanks for that. Let me start with the EC directive and the assumption it comes back in Q1. I know you're planning to seek a stay, but if you could take us through how you see the process unfolding — and if the stay isn't granted, what happens then? Also, on the GRAIL balance sheet: ultimately, if GRAIL ends up having to be divested, how should we think about the capital Illumina would need to commit to that? When it comes to our 2023 guidance, as we said earlier, we've pulled in a few items that were visible. First is the shift to NovaSeq X. We've noted that demand will exceed supply. We've also discussed linearity — we do expect the second half, with revenue climbing quarter by quarter as NovaSeq X reaches the market and customers begin bringing up the instrument and ordering NovaSeq X consumables. We also expect that — we placed a large number of mid-throughput instruments late in 2022 and continue to expect additional NextSeq 1000/2000 placements throughout 2023. As those start operating, you'd anticipate consumables picking up more as the year progresses. We've also mentioned, regarding 2023, some recovery in China during the latter half. Going into the close of '22 and even Q1 2023, China was dealing with COVID-related lingering effects and carryover from the prior year. At present, we think those factors should fade. On top of that, FX headwinds should be less pronounced as we move from the first half into the second half of the year. Given all of that, we still anticipate that revenue and linearity will climb as 2023 progresses, even after factoring in the deceleration in recruitment that has shown up in some of the larger pop-gen projects. Francis, over to you for the second part of the question.
Francis deSouza
executiveSure. So Dan, regarding the GRAIL process, we expect the divestiture order to be issued at the end of Q1, so perhaps the start of Q2. And we plan to apply — if there's no stay tied to it while the appeals are pending, we'll request one. After that, we'll follow the dual track and be pragmatic as we proceed along both routes. On one hand, we'll have a divestiture track in which we collaborate with the European Commission GRAIL and move forward on the divestiture process. We anticipate that unfolding across this year and into next year. In parallel, we have our appeals, and 2 appeals are underway. One concerns jurisdiction, and we expect a decision probably near the end of this year, and the other concerns the prohibition order, and we expect a decision perhaps near the end of this year, perhaps at some point into next year. So those are the 2 paths; regarding capitalization, part of the divestiture track will involve ensuring GRAIL is capitalized going forward. That might come through a mix of strategic partners investing in GRAIL. That could be one route; it could be a multistep route involving initially investment into GRAIL from strategic partners moving toward an IPO; but all of that depends on what the divestiture order says, and that's something we're still discussing. So we'll keep you updated as progress is made.
Dan Arias
analystI'd also like to discuss GRAIL, if that's all right. Joydeep, regarding the 2023 dilution—that $670 million—I'm simply wondering how much flexibility exists within that figure and the spending tied to it. My point is that, clearly, the Galleri forecast is hard to predict at this early stage; so if the revenue outlook were to begin shifting later on, I'm curious how much of what you may need to spend there could be variable in some form. And then Francis, about the GRAIL NHS project and part 1 of that study, the 140,000 asymptomatic population assessment. The NHS documents, if my memory serves, said the initial results were anticipated in late 2023. Is that still the timeline we ought to have in mind? I'm just—I'm considering your remark about a possible IPO and the outcomes there and what could matter to that process.
Joydeep Goswami
executiveAll right. Dan, thank you for the question. So regarding the GRAIL dilution of roughly $670 million this year, right, a few points on that. A substantial portion of it is going toward continuing to speed up certain clinical trials ahead of the NHS trials finishing, the FDA submission for the Galleri products and, naturally, toward scaling up the sales and marketing needed as the product carries on its successful commercial launch, right? Their commercial launch has gone really well. How we've projected revenues into next year is based on—it's truly based on the run rate we've observed with Galleri as they came out of 2022 plus some of what was in the funnel going into 2023 and particular assumptions about repeat testing surrounding that. So with that said, I will note, and I'll repeat, that GRAIL is held separately, so Francis and I at Illumina don't truly control their—the way they spend their money and the way they run the company. But I will note that during 2022, they did very well in how they managed to modify operating expenses as revenues differed from what some of their initial expectations had been. So we trust GRAIL's management—they're capable managers, and they're skilled at directing their money to the right areas that truly prioritize the clinical trials and the product's commercialization.
Francis deSouza
executiveThen, Dan, I’ll address the NHS contracts. As you mentioned, the GRAIL team holds an agreement with the NHS covering the 140,000-person clinical trial now in progress, and it also covers the following stage, contingent on how the trial performs. So they already have an arrangement with the NHS under which, if the trial satisfies its performance criteria, the NHS will extend this test to 1 million participants across the U.K. during 2024 and 2025, with the NHS paying for it. The readout is expected at the end of this year, perhaps the start of next year; so that remains the timeline envisioned in the contract.
Vijay Kumar
analystI've got a question with 3 parts. Francis, the first one's about revenues. When I look at Q1, I believe the implied guidance is teens declines. That means the back half, as implied, is north of 20% year-on-year revenue growth in order to reach the high singles to low doubles for the annual. What's behind that back half ramp, when I view it on a year-on-year basis? I know you brought up the historical launch year as a comp. But could you just take us through the visibility you have into those numbers? And Joydeep, one about margins for you. Why did gross margin fall sequentially Q-on-Q when I compare Q4 with Q3? If Q1 starts at 17% operating margins for core Illumina, would that suggest an exit rate in the high 20s for core Illumina by Q4 '23?
Joydeep Goswami
executiveI'll start, and I'll share a little about how revenues ramp in the back half, okay? So let me start with the first half — the first quarter and the first half, right? The first half of 2021 gave us very strong quarters. We had record NovaSeq 6000 shipments, as you may remember, at the start of that year, while COVID surveillance revenues were still ramping. For this year, since in Q1 we've stated our plan is to deliver roughly forty to fifty NovaSeq X units — a figure well below the demand we're seeing — you'd anticipate that growth rates will be held back during the first half as we scale NovaSeq X and the associated consumables purchases. Then in the back half of the year, things shift somewhat, correct? Shipments of NovaSeq X get much closer to running at full capacity, and you pick up the added lift from customers beginning to buy NovaSeq X consumables. Additionally, certain factors acted as drags during this year—namely China COVID and a general decline in COVID surveillance throughout the latter half. So, as you noted, both the percentage growth rates late in the year and the actual revenue begin to climb in the second portion of the year; I hope that clarifies things; regarding margins, allow me to address gross margin first. When you look at gross margin moving down from one quarter to the next — and since this is a launch year, that's the main factor — the drop is really driven by NovaSeq X shipping in Q1, which, as we told you, would begin this year at a lower margin. We expect that margin to keep improving as we move toward the latter part of 2023, with much greater factory utilization and, naturally, the usual gains in process efficiency starting to emerge. The same holds true for operating margin, I would say. My read of your question is that you start from a fairly modest operating margin, and for us, once gross margin and the revenue profile both strengthen, operating margin should follow as we head into the second half of the year. Really, it's mostly a matter of arithmetic there, because a considerably stronger revenue profile absorbs operating expense, and that expense remains roughly level across the year. So I hope that offers you some sense of how we've gone about planning for the year.
Tejas Savant
analystTwo things from me. First, Francis, on GRAIL — going back to Dan's question. Of that $670 million in OpEx this year, how much is specifically linked to the NHS clinical trial that presumably drops off starting in '24? And could there be some delay or an evaluation period while results come in from that, before the 1 million paid pilot begins? Second, on NovaSeq X pull-through assumptions: looking back at the 6000 launch, you were close to almost 1 million in pull-through about 6 quarters in. Couldn't you fairly easily go past that — for instance, six quarters into the X launch or in the back half of '24 — should that number come in around 1.3 million, 1.4 million-plus? Does that sound right?
Francis deSouza
executiveThanks for asking, Tejas. I'll handle part of it, and then Joydeep will jump in if he has anything to add. Let me start with the GRAIL question and how much of that $670 million relates to the NHS trial, and whether there's any possibility the readout or the next phase gets delayed. Part of it does, and we haven't actually broken out that $670 million. Some of that is, though it isn't most of it. So quite a few things are happening at GRAIL. Beyond the NHS trial, they've also got studies underway for the FDA submission, and they aim to complete the final submission near the end of next year. As a result, they're right in the middle of the FDA process. That said, one piece relates to the NHS trial. And as you point out, that piece shifts from being a pure cost to GRAIL at present—for this 140,000-person trial—to a paid rollout next year, beginning next year and spanning 2 years, reaching 1 million people. There's going to be a fairly meaningful and favorable economic change for GRAIL in the coming year. On timing: the NHS worked really carefully and thoroughly alongside GRAIL when mapping out this trial; and since GRAIL had previously run so many large-scale studies, it had a solid grasp of how to evaluate the incoming data and what would be required to reach the conclusion the NHS is seeking. As a result, we aren't anticipating any holdups tied to the data analysis currently underway, and none have surfaced so far. We absolutely anticipate that they will reach that readout by the close of this year or the start of next year. Similarly, given how strong this test is and how eager the NHS is to deploy it as a central element of their fight against cancer, their plan is to complete the readout as responsibly and swiftly as they can. Once the demonstrated performance satisfies the criteria, they intend to move to rollout as fast as possible. So the NHS has enormous motivation here, again owing to the potential life-saving advantages this test offers. And clearly, motivation exists on the GRAIL side as well. As a result, I don't expect anything to hold things up between the readout and when the test is rolled out afterward. On the 6000 pull-through, we've said this before and you've heard it from us already: we genuinely anticipate it will probably require somewhere in the range of the first to the second year before we hit a steady level on pull-through. You pointed out that we reached that point on the 6000 in about that same span. So first, that is indeed the timeframe we're expecting, and we'll continue to update you as we move through the process. As all of you are aware—and to clarify for those who may not be—before reaching that stage, the figures are still too unpredictable to be a reliable input for modeling purposes. The reason is that when you release a substantial quantity of new instruments and customers start ramping up, pull-through can change considerably week to week and quarter to quarter. That's why a full year is needed to place enough instruments in the field for the metric to carry real meaning. Also, as you mentioned, once the X reaches a steady unit count, we're quite confident that the eventual pull-through number for the X will land well above the figure we saw with the 6000 — this stems from the X's power, how quickly it turns around, and the fact that an X can handle far more work across a year.
Sung Ji Nam
analystMoving on to another question about GRAIL. Francis, I'd really like to hear your perspective — you mentioned the FDA Breakthrough Designation for the Galleri test, and I understand that, but it's still somewhat uncharted territory when it comes to navigating the FDA process and perhaps securing wider Medicare reimbursement. So could you walk us through what efforts are underway to push those things forward — to make progress in that direction?
Francis deSouza
executiveYes, absolutely. Let me cover a few points. First, as you mentioned, GRAIL has managed to secure Breakthrough Designation from the FDA, and by now they've been collaborating with the FDA for a number of years on designing the studies that will form part of the eventual submission. So they've been working jointly with the FDA. And while doing so, they've already filed some of the modules tied to the FDA submission, and they intend to submit the final module at the end of next year, possibly stretching into the start of the year after. So good progress is being made. The other major step with the FDA, which truly breaks new ground, is that they've been in discussions with the FDA about including data from the NHS trial as part of the FDA submission; that's really powerful, because it's a very large trial; and so it keeps adding to the body of evidence that GRAIL was able to gather and submit to the FDA; and so I think — we're beginning to see the payoff from that strong working relationship between GRAIL and the FDA. And as you know, once you have FDA approval, that's a fairly significant step forward when it comes to securing broad reimbursement in the United States, which is a really, really big value creation point from GRAIL's perspective. So you'll see both of those things unfold over the next couple of years. You'll see the big NHS shift from a trial to a rollout, a population rollout, beginning with the 1 million people and then going population-wide following the 1 million people rollout in the first 2 years. And at the same time, you'll see progress in the U.S. with the final FDA submission at the end of next year and then the path toward broad reimbursement in the U.S.
David Westenberg
analystCongratulations once more to Joydeep. So 2, I'll begin by asking directly. A lot of the lab companies in our coverage are discussing cutting their cash burn, and they're quite enthusiastic about NovaSeq X — some are even excited about moving from NextSeq over to NovaSeq. So could you help us square their wish to lower cash burn with your expectation that they'll spend more with you? My second question continues on the pricing topic. Why shouldn't we be worried about the new $99 Complete Genome — the Complete Genomics offering — announced today?
Francis deSouza
executiveThanks for the question, Dave. I'll take them one at a time. First, what you're hearing from lab companies matches what we hear: they're genuinely excited about the X — once again, its power, its performance, its turnaround time, and the economics that come with it. I've mentioned that more and more, people will regard those economics as table stakes when applying for and securing new grants. But for lab companies as well, particularly in the current environment, as they try to extract as much as possible from their operations, they view the X as the route to achieving that, and its superior economics will support them in lowering cash burn and trimming their capital needs down the road. So we absolutely expect that to feature in conversations with our customers. In the same way, we're seeing this on the NextSeq side, correct? Customers are seeing more demand arriving. Their question becomes whether to purchase the next NextSeq or to fundamentally rework their cost structure and shift to the X. That's partly why demand is running above our expectations from 2 segments: first, the clinical segment — and we've noted that preorders arriving include a larger share of clinical customers than anticipated; and second, customers who are new to Illumina and new to high-throughput. That dynamic is already reflected in the preorder figure. On competitive dynamics: one thing that has us quite excited is that in our conversations with customers, they grasp very quickly that when comparing which system to purchase, they really examine — they need to examine the total cost of ownership for operating these sequencers. And that's a distinctive aspect of the Illumina lineup in this area—beginning with the NextSeq 1000/2000 and now extending to the NovaSeq X—namely that we've integrated things like the compute for primary, secondary, and in certain cases even portions of tertiary pipelines directly into the instrument itself, along with features we engineered in such as lossless data compression. So once they begin comparing prices, the cost of sequencing isn't the only factor they must consider; they also have to weigh the related compute expenses and the storage expenses they'd incur with any other sequencer available on the market. And one point I raised regarding the X is that the compute-related savings alone from the NovaSeq X will deliver more than $1 million in savings across a 4-, 5-year span. So that's genuinely exciting for them. Setting aside real estate needs, setting aside the time required to post-process your data—all of those matter, but they likewise recognize that the X's total cost of ownership is far superior thanks to those integrated capabilities.
Joydeep Goswami
executiveYes. Francis, to build on that point — David, you’d raised the question, and yes, cash constraints exist when people are trying to cut cash burn. But it’s key to recognize, first, that sequencing sits right at the core of the value these companies — and even academic institutions — are creating, correct? So they want to do more sequencing, because sequencing delivers answers at scale that other technologies simply don’t provide. I think the second point Francis raised matters a great deal, right — when they examine their cash burn, something like the X or a NextSeq 1000/2000 actually lets them lower spending elsewhere, such as around storage or compute or other areas, right, and lets them steer their investments more favorably into areas that add value. That’s a really significant point as you think it through. And then the third thing is simply what they’re doing in elasticity, demand elasticity, or new applications that Francis and Susan and others noted earlier, which is shifting toward things they haven’t done with the NovaSeq 6000s or any other instruments before, which really then draws through the elasticity we expect to see beginning in 2023 but really accelerating in 2024 and beyond as the Xs become fully entrenched.
Sallilyn Schwartz
executiveAll right, thanks for being with us today. Just a reminder that you can find a replay of this call in the Investors section of our website. That wraps up our call, and we hope to see you at the conferences and other events coming up.
Operator
operatorAnd this concludes today's call. You may disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.